Eloralintide: The Selective Amylin Agonist With 20% Weight Loss
Eloralintide (LY3841136) is a selective amylin receptor agonist. The 48-week phase 2 trial, 20% weight loss, unusually mild gut effects, and how it compares with CagriSema.
Peptide Therapy
GLP-1 Weight Loss Peptides
9 articles on GLP-1 Weight Loss Peptides by Dr. med. univ. Julian Douwes: Eloralintide: The Selective Amylin Agonist With 20% Weight Loss; and more.
01
02
Native GLP-1 (7-36 Amide): Why "Pure GLP-1" Fails as a Drug
Native GLP-1 7-36 amide is the real human incretin hormone — and it lasts about two minutes in blood. What the infusion trials showed and why analogues replaced it.
03
Liraglutide: The First GLP-1 for Weight Loss, Reassessed
Liraglutide (Saxenda, Victoza) was the first GLP-1 approved for obesity. What SCALE and LEADER showed, the full titration schedule, and where a daily shot still wins.
04
Mazdutide: The GLP-1/Glucagon Dual Agonist Approved in China
Mazdutide (Xinermei, IBI362) is a GLP-1/glucagon dual agonist approved in China. GLORY-1, GLORY-2 and US phase 2 results, dosing to 9 mg, and how it differs from tirzepatide.
05
Tirzepatide: The Dual GIP/GLP-1 Agonist in Full
Tirzepatide (Mounjaro, Zepbound) in depth: 21% weight loss in SURMOUNT-1, randomised outcome data in sleep apnoea, HFpEF and MASH, the full titration schedule and the trade-offs.
06
Retatrutide Dosage Protocol: Titration Schedule, Starting Dose, and Clinical Expectations
Complete retatrutide dosage guide: starting doses, titration schedule, side effect management by phase, monitoring labs, and realistic weight loss expectations by week.
07
VK2735 Oral GLP-1 Peptide: What Patients and Clinicians Need to Know in 2026
VK2735 is a dual GIP/GLP-1 agonist from Viking Therapeutics, in Phase 3 as a weekly injection and tested in Phase 2 as a daily tablet. What the data show.
08
Retatrutide vs Semaglutide vs Tirzepatide: The Triple Agonist Compared
A clinical comparison of GLP-1, dual GIP/GLP-1, and triple GIP/GLP-1/glucagon agonists — efficacy, weight loss, muscle preservation, and who qualifies in 2026.
09
Semaglutide: Beyond Weight Loss — A Physician's Assessment
An evidence-based clinical assessment of semaglutide. GLP-1 mechanism, cardiovascular benefits, neuroprotective signals, muscle loss concerns, and who should and should not use it.
